| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78fe25c0f2366e39bd129deac55f7cc4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0431
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0487
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F3-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F3-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate |
2018-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c26ccecfa0f401068346404c8aa62f1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06422540c9190240b9141a16c98a8b9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec4222aaf6e91764fe52771a56021e3 |
| publicationDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019367537-A1 |
| titleOfInvention |
In vivo stable hg-197(m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics) |
| abstract |
The present invention relates to in vivo stable 197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer. |
| priorityDate |
2017-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |